Author: Alfred L.

The 2024 American Epilepsy Society (AES) Annual Meeting was a dynamic gathering of clinicians, researchers, advocates, and caregivers committed to

Our family first found out about our daughter Adeline’s SCN2A diagnosis in an online message. The message had been sitting

We will be hosting a SCN2A families only Town Hall this Thursday, 9/5/2024 at 12:00PM EST where we will be

Encouraging Initial Clinical Data for Praxis’ PRAX-222 in SCN2A Gain-of-Function DEEFirst in-human data for PRAX-222, an antisense oligonucleotide (ASO) in

With International SCN2A Awareness Day fast approaching, we are reflecting on the progress made last year and turning our attention

During the holiday season leading up to Eliana’s birth, I can remember that excited feeling of knowing that from this

Industry Relations UpdatesAmerican Epilepsy Society Annual Meeting, Chicago 12/2022 Longboard Pharmaceuticals plans to initiate a phase 1b/2a* clinical study for their

After Eliana was born, we spent five months in the NICU of our local children’s hospital. I quickly realized how

Expanded Access Program May Offer Drug Access to SCN2A Kiddos Prior to a Potential Drug Approval – Praxis has disclosed that

I’m a neuroscience postdoctoral researcher in the lab of Loren Frank at UCSF. I’m fascinated by Scn2a because I want